162 related articles for article (PubMed ID: 30024080)
1. Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors.
Shimazu K; Inoue M; Sugiyama S; Fukuda K; Yoshida T; Taguchi D; Uehara Y; Kuriyama S; Tanaka M; Miura M; Nanjyo H; Iwabuchi Y; Shibata H
Cancer Sci; 2018 Oct; 109(10):3285-3293. PubMed ID: 30024080
[TBL] [Abstract][Full Text] [Related]
2. A Curcumin Analog, GO-Y078, Effectively Inhibits Angiogenesis through Actin Disorganization.
Sugiyama S; Yoshino Y; Kuriyama S; Inoue M; Komine K; Otsuka K; Kohyama A; Yamakoshi H; Ishioka C; Tanaka M; Iwabuchi Y; Shibata H
Anticancer Agents Med Chem; 2016; 16(5):633-47. PubMed ID: 26459768
[TBL] [Abstract][Full Text] [Related]
3. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
[TBL] [Abstract][Full Text] [Related]
4. Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.
Rajitha B; Nagaraju GP; Shaib WL; Alese OB; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
Mol Carcinog; 2017 Jan; 56(1):288-299. PubMed ID: 27128654
[TBL] [Abstract][Full Text] [Related]
5. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
6. The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth.
Bellou S; Karali E; Bagli E; Al-Maharik N; Morbidelli L; Ziche M; Adlercreutz H; Murphy C; Fotsis T
Mol Cancer; 2012 May; 11():35. PubMed ID: 22583931
[TBL] [Abstract][Full Text] [Related]
7. C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFκB in colon cancer cells and xenograft tumors.
Chen C; Liu Y; Chen Y; Xu J
Cancer Biol Ther; 2011 Nov; 12(9):797-807. PubMed ID: 21900746
[TBL] [Abstract][Full Text] [Related]
8. Harmine suppresses bladder tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
Hai-Rong C; Xiang H; Xiao-Rong Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30910851
[TBL] [Abstract][Full Text] [Related]
9. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.
Lai L; Liu J; Zhai D; Lin Q; He L; Dong Y; Zhang J; Lu B; Chen Y; Yi Z; Liu M
Br J Pharmacol; 2012 Feb; 165(4b):1084-96. PubMed ID: 21658027
[TBL] [Abstract][Full Text] [Related]
10. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
Cancer Lett; 2015 Feb; 357(2):557-65. PubMed ID: 25497868
[TBL] [Abstract][Full Text] [Related]
13. CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.
Chung TW; Kim SJ; Choi HJ; Kwak CH; Song KH; Suh SJ; Kim KJ; Ha KT; Park YG; Chang YC; Chang HW; Lee YC; Kim CH
J Mol Med (Berl); 2013 Feb; 91(2):271-82. PubMed ID: 22935775
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
15. Bromophenol curcumin analog BCA-5 exerts an antiangiogenic effect through the HIF-1α/VEGF/Akt signaling pathway in human umbilical vein endothelial cells.
Guo C; Wang L; Jiang B; Shi D
Anticancer Drugs; 2018 Nov; 29(10):965-974. PubMed ID: 30335638
[TBL] [Abstract][Full Text] [Related]
16. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
Gao J; Hu H; Wang X
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
[TBL] [Abstract][Full Text] [Related]
17. Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway.
Fu Z; Chen X; Guan S; Yan Y; Lin H; Hua ZC
Oncotarget; 2015 Aug; 6(23):19469-82. PubMed ID: 26254223
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma.
Sun CC; Zhang YS; Xue X; Cheng YN; Liu HP; Zhao CR; Lou HX; Qu XJ
Eur J Pharmacol; 2011 Sep; 667(1-3):136-43. PubMed ID: 21704029
[TBL] [Abstract][Full Text] [Related]
19. A fibrin antibody binding to fibronectin induces potent inhibition of angiogenesis.
El-Ayoubi F; Amiral J; Pascaud J; Charrin S; Tassel B; Uzan G; Gurewich V
Thromb Haemost; 2015 Jan; 113(1):143-53. PubMed ID: 25252851
[TBL] [Abstract][Full Text] [Related]
20. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]